Pulmonx (LUNG) Competitors

Pulmonx (NASDAQ:LUNG) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.

Do institutionals & insiders have more ownership in LUNG or LQDA?

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by insiders. Comparatively, 30.1% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more risk & volatility, LUNG or LQDA?

Pulmonx has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.

Which has better earnings and valuation, LUNG or LQDA?

Pulmonx has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$68.68M	3.60	-$60.84M	-$1.47	-4.26
Liquidia	$15.61M	62.03	-$78.50M	-$1.63	-7.02

Is LUNG or LQDA more profitable?

Pulmonx has a net margin of -72.01% compared to Liquidia's net margin of -765.38%. Pulmonx's return on equity of -53.88% beat Liquidia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-72.01%	-53.88%	-33.47%
Liquidia	-765.38%	-163.21%	-67.14%

Does the MarketBeat Community prefer LUNG or LQDA?

Liquidia received 168 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 68.14% of users gave Liquidia an outperform vote while only 44.00% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 33 44.00%	Underperform Votes 42 56.00%
Liquidia	Outperform Votes 201 68.14%	Underperform Votes 94 31.86%

Does the media refer more to LUNG or LQDA?

In the previous week, Liquidia had 3 more articles in the media than Pulmonx. MarketBeat recorded 5 mentions for Liquidia and 2 mentions for Pulmonx. Liquidia's average media sentiment score of 0.54 beat Pulmonx's score of 0.51 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend LUNG or LQDA?

Pulmonx currently has a consensus target price of $12.75, indicating a potential upside of 103.67%. Liquidia has a consensus target price of $25.38, indicating a potential upside of 121.81%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Liquidia	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.11

Summary

Liquidia beats Pulmonx on 10 of the 19 factors compared between the two stocks.